Figure 2From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population Overall survival curve; model output. Modelled survival curve using data from the JMEI trial demonstrates that pemetrexed has improved overall survival compared to docetaxel. (PEM: pemetrexed; DOC: docetaxel)Back to article page